Indacaterol, a novel 24-hour β2 -agonist, is effective and well tolerated on multiple dosing in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005
A community-based intravenous medication service has proven to be safe, effective and cost-effective for patients with acute respiratory illness Source: Annual Congress 2010 - Does cost-effectiveness go together with best quality of treatment? New drivers in medicine Year: 2010
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Formoterol-HFA pMDI is effective and well tolerated in children with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 712s Year: 2006
Budesonide/formoterol is a well-tolerated long term maintenance therapy for COPD Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005
Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002
Medical thoracoscopy (MT): A safe and effective strategy in the diagnosis and treatment of patients presenting life threatening comorbidities. Association with clinical outcome Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010
Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients Source: Eur Respir J, 53 (6) 1801824; 10.1183/13993003.01824-2018 Year: 2019
Single-dose indacaterol, a novel 24-hour β2 -agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019
Fibreoptoc bronchoscopy is safe in patients with poor pulmonary function Source: Eur Respir J 2003; 22: Suppl. 45, 58s Year: 2003
Once daily ciclesonide delivered via pMDI is effective and safe for the treatment of mild-to-moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 208s Year: 2006
Home Intravenous Antibiotic Therapy (HIVAT) for adult bronchiectasis patients: safe, efficacious and cost-effective Source: Virtual Congress 2021 – Bronchiectasis Year: 2021
Is outpatient control of long-term noninvasive ventilation feasible in COPD patients? Source: International Congress 2019 – Hot topics in noninvasive ventilation Year: 2019
Is air travel safe for those with lung disease? Source: Eur Respir J 2008; 32: 1423-1424 Year: 2008
Factors influencing best tolerated dose of pirfenidone (PFD) in patients with IPF Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020
Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002